Volume 12, Issue 4 (Oct & Nov 2018)                   payavard 2018, 12(4): 0-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Gholamhoseini M T, Barouni M, Afsharzadeh N, Sirizi M J. Cost-Effectiveness of Growth Hormone (Somatropin) for the Treatment of Children with Short Stature. payavard. 2018; 12 (4)
URL: http://payavard.tums.ac.ir/article-1-6591-en.html
1- Master of Science in Health Economics, School of Management and Medical Information, Kerman University of Medical Sciences, Kerman, Iran
2- Associate Professor, Health Economics Department, School of Management and Medical Information, Kerman University of Medical Sciences, Kerman, Iran , mohsenbarouni@yahoo.com
3- Bachelor of Science in Microbiology, Kerman Health Insurance Organization, Kerman, Iran
4- Ph.D. in Strategic Management, Kerman Health Insurance Organization, Kerman, Iran
Abstract:   (131 Views)
Background and Aim: One of the common problems of children in the world is short stature.. Due to the high costs of treatment, the present study aimed at the Cost-effectiveness of growth hormone (Somatropin) for the treatment of children with short stature in Kerman Province.
Materials and Methods: This research is an economic evaluation. The population of the study consisted of all persons who had medical records in the health insurance office of Kerman province, 49 of whom were selected as samples.. The cost was calculated from two patient and insurer prespective. This information was collected through a researcher-made form by interviewing the patients and reviewing the records of the health insurance office. To calculate the outcomes, two consequences, QALY and increase in height were used. For cost effectiveness analysis, the ICER formula and TreeAge software were used and compared with a threshold of 3 times GDP per capita.
Results: Findings showed that the share of patient's treatment costs was 5,092,964,520 Rials and the share of expenses of Health Insurance Organization of Kerman province was 71,175,443,448 Rials. Incremental cost-effectiveness ratio based on QALY criterion and from the perspective of the patient and the health insurance organization was 743,133 Rials and 9,846,567 Rials, respectively. Sensitivity analysis of non-deterministic parameters of the model showed that they had no effect on the cost effectiveness of treatment with growth hormone.
Conclusion: According to the results, the treatment of short-stature children with growth hormone is cost effective and this result can be considered by policy makers of the health system.
     
Type of Study: Research | Subject: Hospital Managment
ePublished: 2018/11/21

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2018 All Rights Reserved | Journal of Payavard Salamat

Designed & Developed by : Yektaweb